SI1572167T1 - Transdermalni buprenorfinski dozirni reĹľim za analgezijo - Google Patents

Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Info

Publication number
SI1572167T1
SI1572167T1 SI200331365T SI200331365T SI1572167T1 SI 1572167 T1 SI1572167 T1 SI 1572167T1 SI 200331365 T SI200331365 T SI 200331365T SI 200331365 T SI200331365 T SI 200331365T SI 1572167 T1 SI1572167 T1 SI 1572167T1
Authority
SI
Slovenia
Prior art keywords
buprenorphine
dosage form
dosage
analgesia
dosage regimen
Prior art date
Application number
SI200331365T
Other languages
English (en)
Slovenian (sl)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI1572167T1 publication Critical patent/SI1572167T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331365T 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo SI1572167T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
EP03813444A EP1572167B1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
SI1572167T1 true SI1572167T1 (sl) 2008-12-31

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331365T SI1572167T1 (sl) 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Country Status (16)

Country Link
US (1) US7270830B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572167B1 (cg-RX-API-DMAC7.html)
JP (2) JP5054893B2 (cg-RX-API-DMAC7.html)
AT (1) ATE400258T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003297073A1 (cg-RX-API-DMAC7.html)
CA (1) CA2510223C (cg-RX-API-DMAC7.html)
CY (1) CY1108384T1 (cg-RX-API-DMAC7.html)
DE (1) DE60322102D1 (cg-RX-API-DMAC7.html)
DK (1) DK1572167T3 (cg-RX-API-DMAC7.html)
ES (1) ES2310262T3 (cg-RX-API-DMAC7.html)
IL (1) IL169056A (cg-RX-API-DMAC7.html)
MX (1) MXPA05006334A (cg-RX-API-DMAC7.html)
NZ (1) NZ539936A (cg-RX-API-DMAC7.html)
PT (1) PT1572167E (cg-RX-API-DMAC7.html)
SI (1) SI1572167T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004054553A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) * 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
CA2529983C (en) * 2003-07-25 2010-07-20 Euro-Celtique S.A. Preoperative treatment of post operative pain
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2010047681A1 (en) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
MX2018010367A (es) * 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2020124073A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
PT1485051E (pt) 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug

Also Published As

Publication number Publication date
JP2006513184A (ja) 2006-04-20
PT1572167E (pt) 2008-10-03
CA2510223C (en) 2017-09-12
DK1572167T3 (da) 2008-10-13
ATE400258T1 (de) 2008-07-15
JP5054893B2 (ja) 2012-10-24
AU2010201479A1 (en) 2010-05-06
ES2310262T3 (es) 2009-01-01
US20040126416A1 (en) 2004-07-01
AU2003297073A1 (en) 2004-07-09
JP2010285457A (ja) 2010-12-24
WO2004054553A9 (en) 2005-09-15
WO2004054553A1 (en) 2004-07-01
EP1572167A1 (en) 2005-09-14
DE60322102D1 (de) 2008-08-21
EP1572167B1 (en) 2008-07-09
EP1572167A4 (en) 2007-01-10
CY1108384T1 (el) 2014-02-12
NZ539936A (en) 2007-06-29
IL169056A (en) 2012-01-31
MXPA05006334A (es) 2005-08-26
CA2510223A1 (en) 2004-07-01
AU2010201479B2 (en) 2012-11-01
US7270830B2 (en) 2007-09-18

Similar Documents

Publication Publication Date Title
DK1572167T3 (da) Transdermal buprenophindoseringsbehandlingsplan for analgesi
IS6702A (is) Fentanyl lyfjablanda til lyfjagjafar í nef
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
DK1646328T3 (da) Behandling af afhængighedsophör
GB2396108B (en) Treatment of pain
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE69814669D1 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
MX9804797A (es) Nuevos compuestos con efecto analgesico.
MX9804798A (es) Nuevos compuestos con efecto analgesico.